

Supplementary Table S3: Univariate OS Analysis

| Variables | Pt# | Death# | Median OS (months; 95%CI) | HR (95%CI) | Pvalue* |
|--|-----|--------|------------------------------|-----------------|---------|
| Whole Cohort | 199 | 55 | NR | | |
| Age at Diagnosis (5-year increase) | | | | 1.12(0.98-1.28) | 0.087 |
| Charlson Score (12 missing) (1-unit increase) | | | | 1.13(0.93-1.38) | 0.22 |
| NACT Cycle Group | | | | | |
| 3 | 73 | 21 | 33.3(27-NE) | 1 | 0.008 |
| 4 | 70 | 13 | NR | 0.57(0.28-1.14) | |
| >=5 | 56 | 21 | 28.9(19.7-NE) | 1.64(0.89-3) | |
| 4 | 70 | 13 | NR | 1 | 0.008 |
| 3 | 73 | 21 | 33.3(27-NE) | 1.76(0.88-3.52) | |
| >=5 | 56 | 21 | 28.9(19.7-NE) | 2.88(1.43-5.77) | |
| Histology | | | | | |
| Others | 16 | 8 | 23.6(19.8-29.5) | 1 | 0.034 |
| High Grade Serous | 183 | 47 | NR | 0.45(0.21-0.96) | |
| Stage | | | | | |
| III | 66 | 15 | NR | 1 | 0.659 |
| IV | 133 | 40 | NR | 1.14(0.63-2.07) | |
| BRCA | | | | | |
| No mutation | 139 | 46 | 33.3(28.9-NE) | 1 | 0.009 |
| BRCA1/2 Mutation | 30 | 1 | NR | 0.09(0.01-0.65) | |
| Not tested | 30 | 8 | NR | 1.18(0.56-2.5) | |
| NACT Regimen (12 missing) | | | | | |
| Paclitaxel Weekly/ Carboplatin | 134 | 41 | NR | 1 | 0.765 |
| Others | 53 | 11 | NR | 0.9(0.46-1.76) | |
| NACT Indication*** | | | | | |
| Patient factors | 60 | 22 | 36.3(20.2-NE) | 1 | 0.053 |
| Disease factors | 139 | 33 | NR | 0.59(0.34-1.01) | |
| Response on Imaging after 2-3 NACT Cycles | | | | | |
| Response | 181 | 48 | NR | 1 | 0.035 |
| No response/progression | 18 | 7 | 29.5(14.8-29.5) | 2.31(1.04-5.14) | |
| Optimal Debulking | | | | | |
| No | 18 | 8 | 36.3(13.8-NE) | 1 | 0.286 |
| Yes | 181 | 47 | NR | 0.67(0.31-1.41) | |
| CGR | | | | | |
| No | 60 | Sup | 33.3(20.1-NE) | 1 | 0.003 |
| Yes | 139 | 30 | NR | 0.46(0.27-0.78) | |
| Adjuvant Therapy (4 missing)** | | | | | |

| | | | | |
|-----|-----|----|-----------------|-------|
| No | 15 | 5 | 1 | 0.418 |
| Yes | 180 | 49 | 0.72(0.33-1.60) | |

*Log-rank test is applied to obtain p-value for categorical variables and CoxPH model is used to obtain p-value for continuous variables.

**CoxPH model with counting process is modeled for time dependent variable.

*** Patient factors include Alletti Score, comorbidity, venous thromboembolism, clinical trial, or other. Disease factors include Stage IV unresectable, extent of disease on imaging, extent of disease on laparoscopy, extent of disease requiring thoracic surgery.